Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study

This phase Ib, non‐randomized, open‐label study evaluates the safety and tolerability of ruxolitinib in combination with nilotinib and prednisone in patients with naïve or ruxolitinib‐resistant myelofibrosis (MF). A total of 15 patients with primary or secondary MF received the study treatment; 13 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayala, Rosa, Fernández, Rafael Alonso, García‐Gutiérrez, Valentín, Alvarez‐Larrán, Alberto, Osorio, Santiago, Sánchez‐Pina, Jose M., Carreño‐Tarragona, Gonzalo, Álvarez, Noemi, Gómez‐Casares, María Teresa, Duran, Antonia, Gorrochategi, Julian, Hernández‐Boluda, Juan Carlos, Martínez‐López, Joaquín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Haematologic Malignancy ‐ Myeloid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188506/
https://www.ncbi.nlm.nih.gov/pubmed/37206258
http://dx.doi.org/10.1002/jha2.685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188506/
https://www.ncbi.nlm.nih.gov/pubmed/37206258
http://dx.doi.org/10.1002/jha2.685

Ejemplares similares